Last $4.41 USD
Change Today -0.30 / -6.37%
Volume 116.7K
FCSC On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

fibrocell science inc (FCSC) Snapshot

Open
$4.71
Previous Close
$4.71
Day High
$4.71
Day Low
$4.07
52 Week High
06/20/13 - $7.20
52 Week Low
04/16/13 - $3.03
Market Cap
180.1M
Average Volume 10 Days
121.8K
EPS TTM
$-1.08
Shares Outstanding
40.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FIBROCELL SCIENCE INC (FCSC)

fibrocell science inc (FCSC) Related Bloomberg News

View More Bloomberg News

fibrocell science inc (FCSC) Related Businessweek News

No Related Businessweek News Found

fibrocell science inc (FCSC) Details

Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing various treatments for skin diseases and conditions with unmet medical needs. The company, through its proprietary autologous fibroblast technology, Fibrocell, develops biologic solutions and medical applications of azficel-T for restrictive burn scarring and vocal cord scarring conditions; and biologic products for patients with rare genetic skin and tissue disorders. It has collaboration agreements with Intrexon Corporation for using genetically-modified fibroblasts for treating rare and serious skin, and connective tissue diseases; and University of California, Los Angeles to focus on skin-derived stem cells and other ways to convert skin cells to other cell types. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

58 Employees
Last Reported Date: 03/17/14
Founded in 1995

fibrocell science inc (FCSC) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.0K
Vice President of Operations-Scientific Affai...
Total Annual Compensation: $188.0K
Executive Vice President of Marketing
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2012.

fibrocell science inc (FCSC) Key Developments

Fibrocell Science, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Fibrocell Science, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter ended December 31, 2013, Fibrocell reported a net loss attributable to common stockholders of the company of $5.7 million, or $0.14 per share, compared to a net loss of $21.5 million, or $0.89 per share, for the same period in 2012. The company used $4.0 million in cash for operations during the fourth quarter of 2013. Revenue from product sales were $44,000 against $40,000 a year ago. Operating loss was $5,651,000 against $12,647,000 a year ago. Loss from continuing operations before income taxes was $5,654,000 against $21,545,000 a year ago. Loss from continuing operations was $5,654,000 or $0.14 per basic and diluted share against $21,531,000 or $0.89 per basic and diluted share a year ago. For the year ended December 31, 2013, Fibrocell reported a net loss attributable to common stockholders of the company of $30.6 million, or $1.03 per share, compared to a net loss of $23.2 million, or $2.59 per share, for the year ended 2012. Revenues for 2013 were $200,000, a 31% increase compared to $153,000 in 2012. Operating loss was $30,503,000 against $29,390,000 a year ago. Loss from continuing operations before income taxes was $30,635,000 against $26,126,000 a year ago. Loss from continuing operations was $30,635,000 or $1.03 per basic and diluted share against $23,194,000 or $2.59 per basic and diluted share a year ago. Net cash used in operating activities was $20,075,000 against $22,575,000 a year ago.

Fibrocell Science, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 10:30 AM

Fibrocell Science, Inc. Presents at The 21st Annual Future Leaders in the Biotech Industry Conference, Mar-28-2014 10:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Gregory L. Weaver, Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer, Corporate Secretary and Director.

Fibrocell Science, Inc., Q4 2013 Earnings Call, Mar 17, 2014

Fibrocell Science, Inc., Q4 2013 Earnings Call, Mar 17, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FCSC:US $4.41 USD -0.30

FCSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FCSC.
View Industry Companies
 

Industry Analysis

FCSC

Industry Average

Valuation FCSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 932.2x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 661.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROCELL SCIENCE INC, please visit www.fibrocellscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.